Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis

Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent LDL-C lowering agents. However, few head-to-head studies evaluated the efficacy on the lowering in other atherogenic apolipoproteins and safety of PCSK9 inhibitors at different dosages as an add-on statins th...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yi-Ting, Ho, Li-Ting, Hsu, Hsin-Yin, Tu, Yu-Kang, Chien, Kuo-Liong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014015/
https://www.ncbi.nlm.nih.gov/pubmed/35444537
http://dx.doi.org/10.3389/fphar.2022.832614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014015/
https://www.ncbi.nlm.nih.gov/pubmed/35444537
http://dx.doi.org/10.3389/fphar.2022.832614

Ejemplares similares